Cycloastragenol vs. Astragaloside IV: A Systematic Analysis of Bioavailability and Efficacy in Telomerase Activators

In the modern Healthy Aging sector, the comparison between Cycloastragenol (CAG) and Astragaloside IV (AS-IV) is becoming a technical focal point in the fields of telomerase activation and cellular anti-aging. This article provides a systematic analysis of the fundamental differences between these two key monomers, offering actionable decision-making references for B2B procurement.

AS-IV is a typical triterpenoid saponin, structurally composed of a cycloartane-type triterpene skeleton linked to multiple sugar moieties (such as glucose and xylose). It has a large molecular weight and is overall hydrophilic.

CAG is the aglycone of AS-IV. Its structure is obtained by removing the sugar chains through enzymatic hydrolysis or other biotransformation processes, retaining the triterpene skeleton, which results in a smaller molecular weight and significantly enhanced hydrophobicity.

From a physical-chemical perspective:

• 1 Molecular Weight: CAG is smaller than AS-IV; this small-molecule characteristic favors membrane permeability.
• 2 Lipophilicity: After deglycosylation, CAG’s lipid solubility is enhanced, making it more prone to crossing the lipid bilayer and entering the intracellular environment.



III. Bioavailability: The Small-Molecule Advantage in Overcoming Absorption Barriers



Large glycosides like AS-IV are often limited by multiple absorption barriers during oral administration, including large molecular size, low transmembrane diffusion efficiency, and low permeability in intestinal epithelial cell models (such as Caco-2).



In vivo pharmacokinetic data indicates that the absolute oral bioavailability of AS-IV is low: approximately 2.2%–3.7% in rat models and only about 7% in larger animals like dogs. Literature indicates that the low absorption of AS-IV is primarily related to its large molecular weight rather than being dominated by P-glycoprotein active efflux.



In contrast, CAG, as a small-molecule aglycone, has a smaller molecular mass and stronger lipophilicity, which are considered conducive to easier absorption from the gastrointestinal tract. Research reports suggest that CAG is one of the primary absorbed forms of AS-IV after intestinal hydrolysis, suggesting its dual significance as both a "metabolite + direct supplement."



For finished formulations: Using high-purity CAG in capsules or tablets helps achieve more predictable plasma concentrations, providing a stable pharmacokinetic basis for targeted effects. In topical serums, smaller lipophilic molecules are also more conducive to penetrating the stratum corneum to interact with the skin cell environment.




IV. Pharmacological Core: Telomerase Activation and Anti-Aging Evidence

Telomerase (specifically the hTERT subunit) can delay the shortening process of telomeres, which is widely discussed as a potential target for anti-aging research. Multiple recent in vitro and animal studies show that both AS-IV and CAG can upregulate telomerase-related indicators under high-glucose or oxidative stress conditions.



In research on Nucleus Pulposus Cells (NPCs), both have been confirmed to reduce the expression of the senescence marker p16 and SA-β-gal positive staining. They downregulate apoptotic markers c-C3 and BAX, while upregulating the anti-apoptotic protein Bcl-2 and increasing TERT mRNA and protein levels.



In the field of immune cells, research shows CAG can increase telomerase activity in human CD4 and CD8 T cells, suggesting its potential to delay T-cell immunosenescence. Further studies show CAG stimulates telomerase activity via the CREB-hTERT-Bcl-2 axis and enhances NRF2 activity, promoting hTERT nuclear localization and forming the "NRF2-hTERT-Proteasome" anti-aging network node.




V. Quality Control: From CAS Number to HPLC Fingerprinting

In global trade, standardizing ingredients via CAS numbers is fundamental. High-purity CAG is identified by CAS 78574-94-4, helping to distinguish it from AS-IV and avoiding confusion at the formulation and labeling stages.



Since CAG and AS-IV are closely related, utilizing HPLC to establish clear purity fingerprints is a necessary step in quality control. For 98% purity levels, quality systems must focus on impurity control, including residual saponin intermediates and process by-products.



Furthermore, strict control of heavy metals and microbial counts must follow USP/EP standards. From a sensory perspective, high-purity CAG typically appears as a light-colored powder with good flowability, serving as a reference during initial raw material screening.




VI. Formulation Strategies: Scientific Recommendations




Dimension	Cycloastragenol (CAG)	Astragaloside IV (AS-IV)
Chemical Type	Aglycone (Sapogenin)	Glycoside
MW / Lipophilicity	Small MW, Lipophilic	Large MW, Hydrophilic
Bioavailability	Higher; Primary absorbed form	Low (2.2%–7.4%)
Telomerase Evidence	Strong (hTERT/NRF2)	Moderate (Stress-response)
Application	Premium Anti-Aging	General Wellness
Recommendation	Select based on cost-benefit balance vs. premium positioning.

Decision Recommendations: For "Telomere Science" theme products, high-purity (≥98%) CAG is the scientifically logical choice to build a differentiated narrative and premium positioning. For immune or cardiovascular support formulas, standardized AS-IV remains more feasible in terms of cost-benefit balance and broad-spectrum efficacy.




References
• [1] Zhang Y. et al. Cycloastragenol and Astragaloside IV activate telomerase and protect nucleus pulposus cells from high glucose-induced senescence and apoptosis. Aging (Albany NY). 2021.
• [2] Ip FC, Ng YP, et al. Cycloastragenol is a potent telomerase activator in neuronal cells and human neonatal keratinocytes. NeuroSignals. 2014;22(1):52–63.
• [3] Öner MG. et al. The role of cycloastragenol at the intersection of Nrf2/ARE, telomerase and proteasome in aging-related processes. Free Radical Biology & Medicine. 2022.
• [4] Transport and bioavailability studies of astragaloside IV, an active component of Radix Astragali. Journal of Pharmacy and Pharmacology. 2004;56(10):1149–57.
• [5] ChemicalBook. Astragaloside IV: mechanism of action, pharmacokinetics and toxicity. 2023.
• [6] Chen W. et al. Review of the pharmacological effects of astragaloside IV. Biomedicine & Pharmacotherapy. 2022.
• [7] Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. Frontiers in Pharmacology. 2019.
• [8] Sinoway Industrial Co., Ltd. Astragalus Extract / Cycloastragenol – Product Technical Information.
• [9] Sigma-Aldrich (Merck). Cycloastragenol is a potent telomerase activator in neuronal cells – Technical note SML1448.
• [10] Chemistry Europe. Synthesis and Anti‑Aging Activity Exploration of Cycloastragenol Derivatives. ChemistrySelect. 2025.